Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 1;9:3210. doi: 10.1038/s41598-019-39547-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Chemical inhibition of PERK sensitizes colon cancer cells to 5-Fluorouracil treatment. (A) Total PERK protein was immunoprecipitated from cells as indicated, and western blotting was conducted to measure the level of phosphorylated PERK by use of a pan-pThr/Ser antibody. Cellular level of p-eIF2α was also measured for cells treated as indicated. (B) Western blotting showing the effects of an escalating dose of PERK inhibitor (0 µM, 0.1 µM and 1 µM) on ATF4 in SW620 and SW480 cells w/or w/o Thapsigargin treatment. β-Actin was used as loading control. (C,D) Dose response curves showing effects of the PERK inhibitor (1 µM) in sensitizing SW620 and SW480 cells to 5-FU treatment. (E) Flow cytometric analysis showing the percentage of apoptotic cells (SW620) treated as indicated. (F) Western blot showing the protein level of cleaved PARP which reflects the degree of cell apoptosis (SW620) treated as indicated. * means P < 0.05. Data are represented as mean ± SEM or the mean alone.